MedPath

Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine

Phase 4
Completed
Conditions
Major Depression
Interventions
Registration Number
NCT00532480
Lead Sponsor
Indiana University School of Medicine
Brief Summary

The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain

Detailed Description

This study will measure the activity in different parts of the brain, while the patients are seeing some pictures, using Magnetic Resonance Imaging (MRI) scan. For this study three MRI scans will be conducted. One before the patient begins on any medication, one during the study after 3 weeks of treatment and one after six more weeks of treatment with a standard antidepressant called duloxetine.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
DuolxetineDuloxetineOpen-label duloxetine 30 - 60 mg oral administration
Primary Outcome Measures
NameTimeMethod
17-item Hamilton Depression Rating Scale8 weeks

Standard 17-item rating scale for depression used in clinical trials. A score of 0-7 is considered to be normal. 8 - 13 mild depression. Scores of 20 or higher indicate moderate, severe, or very severe depression, and are usually required for entry into a clinical trial. Range of score: 0 - 50.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Indiana University Adult Psychiatric Clinic

🇺🇸

Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath